PolyPid Ltd. (PYPD) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
No case yet. It builds on the next filing, report or 13F period.
PolyPid Ltd. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 3841, Surgical & Medical Instruments & Apparatus, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
32 managers report a position worth $16.7M between them, and 8 of them hold 80% of it.
High 5.20 at 3:15 pm ET, low 5.17 at 2:45 pm ET.
PolyPid Ltd.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Surgical & Medical Instruments & Apparatus
PYPD (PolyPid Ltd.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.